For the quarter ended March 2024, Viatris (VTRS) reported revenue of $3.66 billion, down 1.8% over the same period last year. EPS came in at $0.67, compared to $0.78 in the year-ago quarter.The reported revenue represents a surprise of -2.12% over the Zacks Consensus Estimate of $3.74 billion. With the consensus EPS estimate being $0.68, the EPS surprise was -1.47%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectat ...

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.67 per share when it actually produced earnings of $0.61, delivering a surprise of -8.96%.Over the last four quarters, the compan ...

Q1 2024 Earnings May 9, 2024 ...

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges • Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter • Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] • Reaffirms 2 ...

Viatris Inc. (VTRS)财报预期 - 分析师们最近对Viatris Inc. (VTRS)盈利预期进行了积极修订[1][2] - VTRS本季度的最准确预估为每股69美分，高于Zacks Consensus Estimate的68美分，显示分析师们最近上调了对VTRS的预估[3] - 公司的Zacks Earnings ESP为+0.74%，显示出积极的盈利预期[3] - 公司的Zacks Rank为3，加上盈利预期积极，投资者可能考虑在财报发布前考虑购买该股票[5] - 最近的盈利预估修订表明Viatris前景看好，可能会在即将发布的财报中取得好成绩[6]

Viatris (VTRS) , a global healthcare company, is scheduled to report first-quarter results on May 9, 2024.The company’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.78%. In the last reported quarter, the company missed on earnings by 8.96%.Factors to ConsiderViatris reports revenues under two divisions in terms of product category —brands and generics.Brand business makes up about two-thirds of the company’s portfolio. This category is ...

The market expects Viatris (VTRS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 9, 2024, might help the stock move higher if these key numbers are better th ...

公司财务信息 - Viatris Inc. (NASDAQ: VTRS)将于2024年5月9日在美国金融市场开盘前公布2024年第一季度财务结果[1] - 公司首席执行官Scott A. Smith和其他高管将于同一日期的美国东部时间上午8:30举行网络研讨会，讨论财务结果[1] 公司信息 - Viatris Inc. (NASDAQ: VTRS)是一家全球医疗保健公司，致力于整合仿制药和品牌药的优势，为全球医疗需求提供更全面的解决方案[3] - 公司总部位于美国，全球设有中心在匹兹堡、上海和印度海得拉巴，提供高质量药品给全球约10亿患者，涵盖从出生到终老、急性病症到慢性疾病的所有生活时刻[4]

文章核心观点 - 全球医疗保健公司Viatris公司任命Corinne Le Goff为首席商务官,加入公司高管团队 [1][3] - Corinne Le Goff拥有25年以上的生物技术和制药行业从业经验,在多个市场和治疗领域有丰富的从业经历 [2][3] - Viatris CEO Scott A. Smith表示Corinne Le Goff的加入将有助于推动公司的长期发展,她在行业内有深厚的理解和丰富的经验 [4] - Corinne Le Goff表示很高兴加入Viatris,并期待与公司高管团队合作,继续推进公司的使命,实现未来的发展机遇 [4] 公司概况 - Viatris是一家全球性医疗保健公司,致力于在通用药和专利药之间架起桥梁,更全面地满足全球医疗需求 [4] - 公司在2022年向全球约10亿患者提供了高质量的药品 [4] - 公司总部位于美国,在匹兹堡、上海和印度海得拉巴设有全球中心 [4] 新任首席商务官背景 - Corinne Le Goff曾担任Imunon公司的总裁兼首席执行官,领导了该公司的组织重塑和品牌重塑工作 [3] - 此前她还曾在Moderna公司担任首席商务官,负责建立商业组织并确保Moderna新冠疫苗的全球供应 [3] - 她还在Amgen公司工作了6年,担任过美国业务总裁、全球产品战略与商业创新高级副总裁以及欧洲区总裁等职务 [3] - Corinne Le Goff拥有巴黎第五大学药学博士学位和巴黎索邦大学工商管理硕士学位 [3]

Vertigo3d There is quite a pronounced valuation gap in the pharmaceuticals sector, with richly priced names like Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) on the high-end of the spectrum, and others like Bristol Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD) on the other end. This brings me to the even lower-priced name, Viatris Inc. (NASDAQ:VTRS) which falls in the deep value category. I last covered VTRS back in June of last year, noting that it wouldn't take much to move the nee ...